PUBLIC HEALTH DIVISION CENTER FOR HEALTH PROTECTION Oregon Psilocybin Services



http://oregon.gov/psilocybin

Change in Facilitator Training Program Curriculum Worksheet

Please use this form to submit material changes to a facilitator training program curriculum OR submit the changes online through the <u>Oregon Psilocybin Services (OPS) – Training Program, Licensing, and Compliance (TLC) system.</u> You must submit a copy of the new curriculum with this worksheet for review. OPS must review and approve curriculum changes which may take several weeks. Thank you for your patience.

Submit this form and a copy of the new curriculum to:

Oregon Psilocybin Services (OPS)
<u>Licensing.Psilocybin@odhsoha.oregon.gov</u>
or mail to:

Oregon Health Authority – Public Health Division RE: OPS Section PO Box 14450 Portland, OR 97293-0450

Date:				
Training Program Na	ame:			
Responsible Party for Training Program:				
Last	First	M.I.		
TLC Training Progra	m ID (if known):	 		
,	escribe the material changes	0, 0		

NI • 1• / /I	•	 41 0 11 ·

Version Approved 6/1/2022

Please indicate the page numbers in your curriculum where the following modules may be found. These are referenced from OAR 333-333-3060.

Page #	Curriculum Modules
	(1) Historical, Traditional, and Contemporary Practices and
	Applications: 12 hours.
	(a) Current and historical use of plant and fungal medicines in
	indigenous and western cultures;
	(b) The Controlled Substances Act and its effect on psilocybin
	research and drug policy; and
	(c) Overview of historical and recent academic research
	(2) Cultural Equity in relation to Psilocybin Services: 12 hours.
	(a) Cultural equity, its relationship to health equity and social
	determinants of health;
	(b) Racial justice, including the impact of race and privilege on
	health outcomes and the impact of systemic racism on individuals and
	communities;
	(c) The impact of drug policy on individuals and communities;

(d) History of systemic inequity, including systemic inequity in delivery of healthcare, mental health and behavioral health services; (e) Intergenerational trauma; and (f) Responsible Referral and Support (3) Safety, Ethics and Responsibilities: 12 hours. (a) Awareness of facilitator's personal bias, including examination of facilitator's motives; (b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and conflict resolution.	
(e) Intergenerational trauma; and (f) Responsible Referral and Support (3) Safety, Ethics and Responsibilities: 12 hours. (a) Awareness of facilitator's personal bias, including examination of facilitator's motives; (b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(d) History of systemic inequity, including systemic inequity in
(f) Responsible Referral and Support (a) Safety, Ethics and Responsibilities: 12 hours. (a) Awareness of facilitator's personal bias, including examination of facilitator's motives; (b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	delivery of healthcare, mental health and behavioral health services;
(a) Safety, Ethics and Responsibilities: 12 hours. (a) Awareness of facilitator's personal bias, including examination of facilitator's motives; (b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(e) Intergenerational trauma; and
(a) Awareness of facilitator's personal bias, including examination of facilitator's motives; (b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(f) Responsible Referral and Support
of facilitator's motives; (b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(3) Safety, Ethics and Responsibilities: 12 hours.
(b) Training on the Oregon Psilocybin Services Act and related laws, regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(a) Awareness of facilitator's personal bias, including examination
regulations, and professional standards for facilitators; including facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	of facilitator's motives;
facilitator scope of practice and expectation of referral when scope of practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(b) Training on the Oregon Psilocybin Services Act and related laws,
practice is exceeded. (c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	regulations, and professional standards for facilitators; including
(c) Training in ethical issues related to psilocybin facilitation, including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	facilitator scope of practice and expectation of referral when scope of
including: (A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	practice is exceeded.
(A) Oregon's Facilitator Code of Ethics; (B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(c) Training in ethical issues related to psilocybin facilitation,
(B) Ethical considerations relating to equity, privilege, bias and power; (C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	including:
(C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(A) Oregon's Facilitator Code of Ethics;
(C) Awareness of increased vulnerability associated with altered states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(B) Ethical considerations relating to equity, privilege, bias and
states of consciousness. (D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	power;
(D) Appropriate use of touch and client consent to physical contact; (E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(C) Awareness of increased vulnerability associated with altered
(E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	states of consciousness.
(E) Appropriate emotional and sexual boundaries between facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(D) Appropriate use of touch and client consent to physical
facilitators and clients both during provision of psilocybin services and at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	contact;
at other times, potential harm to clients and consequences for facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(E) Appropriate emotional and sexual boundaries between
facilitators of breaching those boundaries; (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	facilitators and clients both during provision of psilocybin services and
 (F) Historical and contemporary abuse of power associated with psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and 	at other times, potential harm to clients and consequences for
psychedelics, including sexual, emotional and physical abuse, and implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	facilitators of breaching those boundaries;
implications for facilitators; (G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(F) Historical and contemporary abuse of power associated with
(G) Financial conflicts of interest and duties to clients. (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	psychedelics, including sexual, emotional and physical abuse, and
 (H) Reasonable expectations regarding client outcomes (d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and 	implications for facilitators;
(d) Accurate record keeping and client confidentiality. (e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(G) Financial conflicts of interest and duties to clients.
(e) Awareness of new research related to safety and ethics of providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(H) Reasonable expectations regarding client outcomes
providing psilocybin services and resources for professional development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	(d) Accurate record keeping and client confidentiality.
development following program completion. (f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	
(f) Appropriate measures to mitigate risks associated with psilocybin services, including harm reduction, de-escalation, and	providing psilocybin services and resources for professional
psilocybin services, including harm reduction, de-escalation, and	development following program completion.
	(f) Appropriate measures to mitigate risks associated with
conflict resolution.	psilocybin services, including harm reduction, de-escalation, and

	(4) Psilocybin Pharmacology, Neuroscience, and Clinical Research: 4
	hours.
	(a) Pharmacodynamics and pharmacokinetics of psilocybin;
	(b) Drug and supplement interaction;
	(c) The metabolism of psilocybin and psilocybin products including
	concentration of psilocybin and psilocin in available psilocybin
	products.
	(d) The primary effects and mechanisms of action of psilocybin on
	the brain, including connectivity in the brain and activation of
	serotonin receptors; and
	(e) Key areas of psilocybin research.
	(f) Models of substance use, addiction, and recovery.
	(5) Core Facilitation Skills module shall include the following subjects
	and their application during preparation, administration, and
	integration sessions: 16 hours.
	(a) Client communication, empathy and rapport, including a
	nondirective facilitation approach, cultural attunement and a
	nonjudgmental disposition;
	(b) Response to psychological distress and creating a safe space for
	difficult emotional experiences;
	(c) Physical reactions and side effects of psilocybin;
	(d) Trauma informed care, including physiology of trauma, vicarious
	trauma, empathic stress and compassion fatigue;
	(e) Active monitoring of client-facilitator boundaries specifically
	boundaries related to consent and touch;
	(f) Identification and facilitation of a variety of subjective psilocybin
	experiences, including experiences relating to physiological sensations,
	cognitive, emotional and mystical states, and traumatic memories;
	(g) Appropriate modes of intervention, understanding when
	intervention is necessary, and when a client may need a higher level of
	care;
	(h) Recognizing and addressing adverse behavioral reactions and
	adverse medical reactions; and
	(i) Identification of the unique health, psychological and socio-
	cultural presented by persons with terminal illness; and awareness of
	the appropriate knowledge, skills and approach needed to provide
1	

safe facilitation to such persons in a manner consistent with client
goals, values, heritage, and spiritual practices.
(6) Preparation and Orientation: 16 hours.
(a) Informed consent;
(b) Client information form and intake interview, including
discussion of client's reasons for seeking psilocybin services;
(c) Using the client information form to assist clients in identifying
benefits of referral to specialized treatment services;
(d) Facilitator role and the limits of facilitator's scope of practice;
(e) Trauma informed communication skills;
(f) Identification of client safety concerns, including medical history,
contra-indicated medication and psychological instability;
(g) Appropriate strategies to discuss client safety concerns,
including but not limited to identification of client's support system;
(h) Determination of whether a client should participate in an
administration session;
(i) Client directed safety planning to address identified safety
concerns;
(j) Boundaries between the facilitator and the client including use
of touch;
(k) Understanding of how racial and cultural dynamics affect
interactions between client and facilitator; and
(I) Historical and indigenous modalities of preparation.
(7) Administration: 20 hours.
(a) Dosing strategies and considerations, including:
(A) Experiential differences relating to differing dosages;
(B) Physiological considerations in relation to dosage;
(C) Delivery mechanisms of psilocybin; and
(D) Use of secondary doses.
(b) Effectively working with challenging behaviors during an
administration session, including:
(A) Unexpected client disclosures;
(B) Substance-induced psychosis; and
(C) Suicidality
(c) Traumatic stress and its manifestation during a psilocybin
experience and appropriate facilitator response, including:
(A) Trauma's relationship to the body;

(B) Repressed trauma emerging during a psilocybin experience;
(C) Trauma and traumatic stress resulting from systemic
oppression;
(D) Safety for trauma resolution and risks associated with re-
traumatization; and
(E) Protocols for ensuring facilitator safety and responding to
emergencies.
(d) "Set and Setting" including environmental considerations for
administration session such as lighting, sound and temperature; and
(e) Completion of administration session.
(8) Integration; 12 hours.
(a) Identification of appropriate resources that may assist client
with integration, including resources for:
(A) Interpreting feelings and emotions experienced during
administration session;
(B) Facilitation of positive internal and external changes;
(C) Enhancement of existing supportive relationship
(b) Identification of client safety concerns;
(c) Facilitator scope of practice; and
(d) Discussion of appropriate intervals between administration
sessions and related safety concerns.
(9) Group Facilitation: 16 hours.
(a) Skills required to facilitate psilocybin group sessions, including,
but not limited to:
(A) Assessing client's compatibility with group format;
(B) Set and setting for group facilitation;
(C) Facilitating group communications and dynamics, including
strategies for working with multiple facilitators;
(D) Group agreements, including confidentiality and safety; and
(E) Identifying when a client within a group requires individual
support, removal from a group, or additional intervention.
(b) Group Preparation Sessions;